Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that causes widespread inflammation. It can affect the skin, joints, blood vessels, and multiple organ systems. The exact cause ...

Both flare and persistently active disease (PAD) are common disease activity patterns in patients with systemic lupus erythematosus (SLE). A large prospective multinational cohort study ...

Prolonged remission was observed in 72% of patients with systemic lupus erythematosus (SLE) who were treated with a consistent 200 mg daily dose of hydroxychloroquine. The mean weight-adjusted ...

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest.

In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...

Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." Experts don’t know what ...